biostudies-literatureAskar MAllogen LaboratoriesTakeda Oncology; Telomere Diagnostics, Inc.NHLBI NIH HHSJanssen Scientific Affairs, LLCAlexionGamida Cell Ltd.American Cancer SocietySpectrum Pharmaceuticals, Inc.Novartis Pharmaceuticals CorporationOtsuka America Pharmaceutical, Inc.MesoScale Diagnostics, Inc.The Medical College of WisconsinMatch FoundationAstraZenecaUS National Marrow Donor Program (NMDP) Immunobiology Research Grant ProgramIntramural NIH HHSOptum Healthcare Solutions, Inc.Cellular Dynamics International, Inc.Medical College of WisconsinOnyx PharmaceuticalsJazz Pharmaceuticals, Inc.Otsuka Pharmaceutical Co, Ltd. – JapanGenentech, Inc.Amgen, Inc.University of MinnesotaThe Leukemia &amp; Lym phoma SocietyMiltenyi Biotec, Inc.Medac, GmbHMesoblastSunesis Pharmaceuticals, Inc.Health Research, Inc. Roswell Park Cancer InstituteJeff Gordon Children&apos;s FoundationIncyte CorporationBluebird Bio, Inc.HistoGenetics, Inc.Chimerix, Inc.National Marrow Donor ProgramWellpoint, Inc.National Cancer InstituteBristol Myers Squibb OncologySeattle GeneticsCelgene CorporationPfizer, IncNeovii Biotech NA, Inc.Gilead Sciences, Inc.St. Baldrick&apos;s FoundationSwedish Orphan Biovitrum, Inc.Sanofi USHealth Resources and Services AdministrationCleveland Clinic FoundationOffice of Naval ResearchMedImmuneNational Institute of Allergy and Infectious DiseasesNational Heart, Lung and Blood InstitutePerkin Elmer, Inc.Astellas Pharma USFred Hutchinson Cancer Research CenterPCORINCI NIH HHSGenzyme CorporationMerck &amp; Co, Inc.436-444https://www.ebi.ac.uk/biostudies/studies/S-EPMC5370205biostudies-literatureUnknown23(3)Single-center studies have previously reported associations of MHC Class I Chain-Related Gene A (MICA) polymorphisms and donor-recipient MICA mismatching with graft-versus-host disease (GVHD) after unrelated donor hematopoietic cell transplantation (HCT). In this study, we investigated the association of MICA polymorphism (MICA-129, MM versus MV versus VV) and MICA mismatches after HCT with 10/10 HLA-matched (n = 552) or 9/10 (n = 161) unrelated donors. Included were adult patients with a first unrelated bone marrow or peripheral blood HCT for acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome that were reported to the Center for International Blood and Marrow Transplant Research between 1999 and 2011. Our results showed that neither MICA mismatch nor MICA-129 polymorphism were associated with any transplantation outcome (P < .01), with the exception of a higher relapse in recipients of MICA-mismatched HLA 10/10 donors (hazard ratio [HR], 1.7; P = .003). There was a suggestion of association between MICA mismatches and a higher risk of acute GVHD grades II to IV (HR, 1.4; P = .013) There were no significant interactions between MICA mismatches and HLA matching (9/10 versus 10/10). In conclusion, the findings in this cohort did not confirm prior studies reporting that MICA polymorphism and MICA mismatches were associated with HCT outcomes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationMHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.PMC53702055U24-CA076518N00014-15-1-0848N00014-16-1-2020IRG-91-022-18ZIA LM000022-18P01 CA023766U10 HL069294HHSH250201200016CU24 CA0765185U10HL069294Fernandez-Vina MLee SJSobecks RThomas DFleischhauer KMadbouly AAskar MWang THaagenson MHsu KMajhail NSpellman SRZhang AVerneris MfalseMHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.Single-center studies have previously reported associations of MHC Class I Chain-Related Gene A (MICA) polymorphisms and donor-recipient MICA mismatching with graft-versus-host disease (GVHD) after unrelated donor hematopoietic cell transplantation (HCT). In this study, we investigated the association of MICA polymorphism (MICA-129, MM versus MV versus VV) and MICA mismatches after HCT with 10/10 HLA-matched (n = 552) or 9/10 (n = 161) unrelated donors. Included were adult patients with a first unrelated bone marrow or peripheral blood HCT for acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome that were reported to the Center for International Blood and Marrow Transplant Research between 1999 and 2011. Our results showed that neither MICA mismatch nor MICA-129 polymorphism were associated with any transplantation outcome (P < .01), with the exception of a higher relapse in recipients of MICA-mismatched HLA 10/10 donors (hazard ratio [HR], 1.7; P = .003). There was a suggestion of association between MICA mismatches and a higher risk of acute GVHD grades II to IV (HR, 1.4; P = .013) There were no significant interactions between MICA mismatches and HLA matching (9/10 versus 10/10). In conclusion, the findings in this cohort did not confirm prior studies reporting that MICA polymorphism and MICA mismatches were associated with HCT outcomes.2017-01-01T00:00:00Z2017 Mar2024-11-12T11:04:11.362Z2019-03-26T23:04:33ZS-EPMC53702052798738510.1016/j.bbmt.2016.11.021